HC Deb 10 July 1996 vol 281 c188W
Mr. Gallie

To ask the Secretary of State for Scotland what consideration has been given to the use of synthetic factor 8 for the treatment of haemophilia; and if he will make a statement. [37122]

Mr. Michael Forsyth

Synthetic, or recombinant, factor 8 is a new treatment considered appropriate for some patients with haemophilia. The treatment is an alternative to the plasma-derived factor 8 currently in use and supplied free of charge to the NHS by the Scottish national blood transfusion service. To assist with the costs involved in the acquisition of the new product, which is available only from commercial sources, I have agreed to make available funding of £1.1 million in the current year. Future arrangements will depend on the speed and extent of the transition from plasma-derived factor 8 to recombinant. This will be kept under review.